Global Alzheimer’s Disease Diagnostic Market Research Report- Forecast to 2022

Global Alzheimer’s Disease Diagnostic Market Research Report- Forecast to 2022

ID: MRFR/HC/1597-HCRR | December, 2017 | Region: Global | 90 pages | Half-Cooked Research Reports

Global Alzheimer’s Disease Diagnostic Market Information, by Type (Early-onset Alzheimer's, Late-onset Alzheimer's, Familial Alzheimer's disease), by Diagnostic test (Genetic testing, Neurological exam, Mini-mental state exam (MMSE), Brain imaging and others), by End Users (Clinics, Hospitals, Diagnostic Centers and others) - Forecast Till 2022



Market Synopsis of Global Alzheimer’s Disease Diagnostic Market:


Market Scenario:


Alzheimer’s is a type of dementia which results in memory loss accompanied by problem in thinking and behavior process. Alzheimer's is a progressive disease as it gradually increases with time and damages maximum part of the brain finally destroying brain cells. It has been observed that maximum incidence of this disease is in UK where more than 520,000 people are diagnosed with Alzheimer's disease and the increasing ageing population is the reason which is driving Alzheimer’s disease diagnostic and therapeutic market.


The global market for this is expected to reach USD 12 billion by the end of the forecasted period growing at a CAGR of 10%.


Study Objectives Global Alzheimer’s Disease Diagnostics Market:



  • To provide detail analysis of the market structure along with forecast for the next 7 years regarding various segments and sub-segments of the global  Alzheimer’s disease  diagnostic market  

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors- price analysis, supply chain analysis, Porters Five Force analysis etc.

  • To provide past and estimated future revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospect.

  • To provide country level analysis of the market for segments by type, by diagnostic tests, by end users and other sub segments.

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies and drawing a competitive landscape of the market

  • To track and analyze global competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments.



Global Alzheimer’s disease Diagnostic Market, by Type, 2015 (%):

 


 


Intended Audience



  • Alzheimer’s therapeutics & diagnostics manufacturers

  • Alzheimer’s therapeutics & diagnostics suppliers

  • Private research laboratories

  • Research and development (R&D) companies

  • Market research and consulting service providers

  • Government research laboratories



Key Players for Global Alzheimer’s Disease Diagnostic Market:

Some of the key players in this market are: Eli Lilly and Company (UK), TauRx (Republic of Singapore), Alector LLC (US), Accera, Inc. (US), Treventis Corporation (US), Neuro-Bio Ltd (UK), Cognition Therapeutics Inc. (US) and others.



Segments:


Global Alzheimer’s disease diagnostic market has been segmented on the basis of type which comprises of early-onset Alzheimer's disease, late-onset Alzheimer's disease, familial Alzheimer's disease and more. On the basis of diagnostic tests; the market is segmented into genetic testing, neurological exam, mini-mental state exam (MMSE), brain imaging and others. On the basis of end users; the market is segmented into clinics, hospitals, diagnostic centers and others.



Regional Analysis of Global Alzheimer’s Disease Diagnostic Market:


North America holds the largest market share in global Alzheimer’s disease diagnostic in 2015. The North America Alzheimer’s disease diagnostic market is expected to reach USD 12 Million by the end of the forecast period.


Europe is the second-largest market for Alzheimer’s disease diagnostic. Asia Pacific is expected to be fastest growing region of the Alzheimer’s disease diagnostic market.

The report for
Global Alzheimer’s Disease Diagnostic Market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size in terms of value and volume, technological advancement, macro economical and governing factors of the market. The report provides detailinformation and strategies of top key players in the industry. Along with these it also gives a broad study about different markets segments and regions.

1    Introduction

      1.1    Definition

      1.2    Scope of Study

      1.3    Research Objective

      1.4    Assumptions & Limitations

      1.5    Market Structure

2    Research Methodology

      2.1    Research Process

      2.2    Primary Research

      2.3    Secondary Research



3    Market Dynamics

      3.1    Drivers

      3.2    Restraints

      3.3    Opportunities

      3.4    Challenges

      3.5    Macroeconomic Indicators



4    Market Factor Analysis

      4.1    Porter’s five forces model

            4.1.1    Bargaining Power of suppliers

            4.1.2    Bargaining Power of Customer

            4.1.3    Intensity of Competitor’s

            4.1.4    Threat of New Entrants



5    Global Alzheimer’s disease Diagnostic Market, by Type    

      5.1    Introduction

            5.1.1    Early-onset Alzheimer's

            5.1.2     Late-onset Alzheimer's

            5.1.3     Familial Alzheimer's disease

            5.1.4    Others 



6    Global Alzheimer’s disease Diagnostic Market, by Diagnostic tests 

      6.1    Introduction

            6.1.1    Genetic testing

            6.1.2     Neurological exam

            6.1.3     Mini-mental state exam (MMSE)

            6.1.4    Brain imaging

            6.1.5    Others 



7    Global Alzheimer’s disease Diagnostic Market, by End Users

      7.1    Introduction

            7.1.1    Clinics

            7.1.3     Hospitals

            7.1.4     Diagnostic Centers

            7.1.5    Others 



8    Global Alzheimer’s Disease Diagnostic Market, by Regions

      8.1    Introduction

            8.1.1    Americas    

                8.1.1.1    North America

                8.1.1.2    South America

            8.1.2    Europe

                8.1.2.1    Germany

                8.1.2.2    France

                8.1.2.3    UK

                8.1.2.4    Italy

                8.1.2.5    Spain

                8.1.2.6    Rest of Europe

            8.1.3    Asia Pacific

                8.1.3.1    Japan

                8.1.3.2    China

                8.1.3.3    India

                8.1.3.4    Republic of Korea

                8.1.3.5    Rest of Asia Pacific

            8.1.4    Middle East & Africa



9    Company Landscape

      9.1    Introduction

            9.1.1    Mergers Acquisitions

            9.1.2    Collaborations

            9.1.3    Release/New Product Launches

            9.1.4    Other (Expansion, Updates, Partnership)



10    Company Profile

      10.1    Accera, Inc.

            10.1.1    Company Overview

            10.1.2    Product/Business Segment Overview

            10.1.3    Financials

            10.1.4    Key Developments

            10.1.5    SWOT Analysis

      10.2    Alector LLC        

            10.2.1    Overview

            10.2.2    Product/Business Segment Overview

            10.2.3    Financials

            10.2.4    Key Developments

            10.2.5    SWOT Analysis

      10.3    Cognition Therapeutics Inc.    

            10.3.1    Overview

            10.3.2    Product/Business Segment Overview

            10.3.3    Financials

            10.3.4    Key Developments

            10.3.5    SWOT Analysis

      10.4    Eli Lilly and Company    

            10.4.1    Overview

            10.4.2    Product/Business Segment Overview

            10.4.3    Financials

            10.4.4    Key Developments

            10.4.5    SWOT Analysis

      10.5    Neuro-Bio Ltd

            10.5.1    Overview

            10.5.2    Product/Business Segment Overview

            10.5.3    Financials

            10.5.4    Key Developments

            10.5.5    SWOT Analysis

      10.6    TauRx

            10.6.1    Overview

            10.6.2    Product/Business Segment Overview

            10.6.3    Financials

            10.6.4    Key Developments

            10.6.5    SWOT Analysis

      10.7    Treventis Corporation

            10.7.1    Overview

            10.7.2    Product/Business Segment Overview

            10.7.3    Financials

            10.7.4    Key Developments

            10.7.5    SWOT Analysis 

      10.8    Others

11    Appendix

List of Tables

TABLE 1    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, 2013-2022 (USD MILLION)

TABLE 2    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY TYPE, 2013-2022 (USD MILLION)

TABLE 3    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY DIAGNOSTICS TYPE, 2013-2022 (USD MILLION)

TABLE 4    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY END USERS, 2013-2022 (USD MILLION)

TABLE 5    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY REGION, 2013-2022 (USD MILLION)



List of Figures

FIGURE 1    RESEARCH PROCESS

FIGURE 2    PORTERS FIVE FORCES MODEL

FIGURE 3    GLOBAL ORTHOPEDIC TRAUMA DEVICE SMARKET, BY TYPE

FIGURE 4    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY DIAGNOSTICS TYPE

FIGURE 5    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY END USERS

FIGURE 6    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTIC MARKET, BY REGION

FIGURE 7    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTIC MARKET: COMPANY SHARE ANALYSIS, 2015 (%)